JP2021532057A5 - - Google Patents

Info

Publication number
JP2021532057A5
JP2021532057A5 JP2020552696A JP2020552696A JP2021532057A5 JP 2021532057 A5 JP2021532057 A5 JP 2021532057A5 JP 2020552696 A JP2020552696 A JP 2020552696A JP 2020552696 A JP2020552696 A JP 2020552696A JP 2021532057 A5 JP2021532057 A5 JP 2021532057A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
sequence shown
seq
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020552696A
Other languages
English (en)
Japanese (ja)
Other versions
JP7420730B2 (ja
JP2021532057A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/026173 external-priority patent/WO2019195796A1/en
Publication of JP2021532057A publication Critical patent/JP2021532057A/ja
Publication of JP2021532057A5 publication Critical patent/JP2021532057A5/ja
Priority to JP2024002308A priority Critical patent/JP7728374B2/ja
Application granted granted Critical
Publication of JP7420730B2 publication Critical patent/JP7420730B2/ja
Priority to JP2025134046A priority patent/JP2025166129A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020552696A 2018-04-06 2019-04-05 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体 Active JP7420730B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024002308A JP7728374B2 (ja) 2018-04-06 2024-01-11 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体
JP2025134046A JP2025166129A (ja) 2018-04-06 2025-08-12 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862653731P 2018-04-06 2018-04-06
US62/653,731 2018-04-06
PCT/US2019/026173 WO2019195796A1 (en) 2018-04-06 2019-04-05 A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024002308A Division JP7728374B2 (ja) 2018-04-06 2024-01-11 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体

Publications (3)

Publication Number Publication Date
JP2021532057A JP2021532057A (ja) 2021-11-25
JP2021532057A5 true JP2021532057A5 (https=) 2022-04-06
JP7420730B2 JP7420730B2 (ja) 2024-01-23

Family

ID=66223877

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020552696A Active JP7420730B2 (ja) 2018-04-06 2019-04-05 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体
JP2024002308A Active JP7728374B2 (ja) 2018-04-06 2024-01-11 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体
JP2025134046A Pending JP2025166129A (ja) 2018-04-06 2025-08-12 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024002308A Active JP7728374B2 (ja) 2018-04-06 2024-01-11 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体
JP2025134046A Pending JP2025166129A (ja) 2018-04-06 2025-08-12 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体

Country Status (22)

Country Link
US (3) US11608381B2 (https=)
EP (2) EP3773713B1 (https=)
JP (3) JP7420730B2 (https=)
KR (2) KR20250150148A (https=)
CN (1) CN112040980B (https=)
AU (2) AU2019249273B2 (https=)
CA (1) CA3094400A1 (https=)
DK (1) DK3773713T3 (https=)
ES (1) ES3037632T3 (https=)
FI (1) FI3773713T3 (https=)
HR (1) HRP20250986T1 (https=)
HU (1) HUE072318T2 (https=)
IL (1) IL277634A (https=)
LT (1) LT3773713T (https=)
MX (2) MX2020010547A (https=)
PL (1) PL3773713T3 (https=)
PT (1) PT3773713T (https=)
RS (1) RS67121B1 (https=)
SI (1) SI3773713T1 (https=)
SM (1) SMT202500283T1 (https=)
WO (1) WO2019195796A1 (https=)
ZA (1) ZA202005659B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
JP7328982B2 (ja) * 2018-10-11 2023-08-17 住友化学株式会社 プロピレンオキサイド精製装置、及び、プロピレンオキサイドの製造方法
US11138441B2 (en) * 2019-12-06 2021-10-05 Baidu Usa Llc Video action segmentation by mixed temporal domain adaption
KR20230069969A (ko) * 2020-09-15 2023-05-19 리제너론 파마슈티칼스 인코포레이티드 통증에 대한 lepr 아고니스트의 사용
EP4294257B1 (en) * 2021-02-22 2025-11-05 Regeneron Pharmaceuticals, Inc. Method for diagnosing and treating partial lipodystrophy
CN114456124B (zh) * 2021-12-30 2023-04-21 华南农业大学 一种新利司他半抗原、人工抗原、抗体及其制备方法和应用
CN114469051B (zh) * 2022-01-28 2025-09-23 北京工业大学 一种基于磁共振成像的组织特性评估系统
TW202602926A (zh) 2024-03-15 2026-01-16 美商美國禮來大藥廠 作為治療肥胖症之單一或組合療法之瘦素受體促效抗體
WO2025250961A1 (en) * 2024-05-31 2025-12-04 The Regents Of The University Of Michigan Leptin receptor agonists for treatment of multiple symmetric lipomatosis
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
JP2898040B2 (ja) 1990-01-26 1999-05-31 忠三 岸本 gp130蛋白質に対する抗体
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK0690873T3 (da) 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
FR2733250B1 (fr) 1995-04-21 1997-07-04 Diaclone Anticorps monoclonaux anti-gp130, et leurs utilisations
US6977240B1 (en) 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
AU721129B2 (en) 1996-01-08 2000-06-22 Genentech Inc. WSX receptor and ligands
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
WO1997027286A1 (en) 1996-01-23 1997-07-31 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AU2002359288B2 (en) 2001-10-22 2008-07-31 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
KR100459493B1 (ko) * 2002-01-31 2004-12-03 김기수 골다공증의 발생 위험을 예측하는 방법 및 이를 이용한골다공증의 유전적 위험 인자에 대한 진단 키트
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
DE10353593A1 (de) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
ATE557042T1 (de) 2004-03-23 2012-05-15 Lilly Co Eli Anti-myostatin-antikörper
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
US7307142B2 (en) 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
PL2407486T3 (pl) 2005-08-19 2018-05-30 Wyeth Llc Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
EP1951756B1 (en) 2005-10-06 2015-01-07 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
BRPI0716249A2 (pt) 2006-09-05 2013-09-03 Lilly Co Eli anticorpos antimiostatina
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
WO2009045900A2 (en) 2007-09-28 2009-04-09 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing diseases associated with low bone mass
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
CN102947335B (zh) 2010-04-15 2018-11-06 基因泰克公司 抗多聚遍在蛋白抗体及使用方法
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
KR20130118941A (ko) 2011-02-10 2013-10-30 로슈 글리카트 아게 면역치료법
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
MX2014014891A (es) 2012-06-05 2015-06-17 Regeneron Pharma Metodos para hacer anticuerpos biespecificos completamente humanos usando una cadena ligera comun.
PL3366705T3 (pl) 2012-09-12 2023-09-18 Genzyme Corporation FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素a之抗體及其用途
US20170051062A1 (en) 2014-02-18 2017-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
KR20170135967A (ko) 2015-04-15 2017-12-08 리제너론 파마슈티칼스 인코포레이티드 Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
LT3538554T (lt) 2016-11-08 2025-10-10 Antigeną surišantys baltymai, antagonizuojantys leptino receptorius
CN107760761A (zh) * 2017-11-10 2018-03-06 江苏省农业科学院 一种加强瘦素激发lepr信号转导的方法
SG11202005146VA (en) 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
US10131622B1 (en) 2018-01-03 2018-11-20 Saudi Arabian Upstream Technology Company N-hydroxyalkylated polyamines, methods of making N-hydroxyalkylated polyamines, and fluids containing an N-hydroxyalkylated polyamine
MX2020008991A (es) 2018-03-01 2020-12-10 Regeneron Pharma Metodos para alterar la composicion corporal.
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
KR20210104744A (ko) 2018-12-18 2021-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법
KR20230069969A (ko) 2020-09-15 2023-05-19 리제너론 파마슈티칼스 인코포레이티드 통증에 대한 lepr 아고니스트의 사용

Similar Documents

Publication Publication Date Title
JP2021532057A5 (https=)
US20240325530A1 (en) Combination therapies
ES3037632T3 (en) A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia
CN120815164A (zh) 使用gip/glp1共激动剂用于治疗的方法
RU2006120950A (ru) Антитело к cd40: препарат и способы
EP0762890A1 (en) Treatment of diabetes
JP2020500852A5 (https=)
Aylwin et al. Emerging concepts in the medical and surgical treatment of obesity
Sano et al. Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report
JP2024512255A5 (https=)
JP2001512483A (ja) レプチンレセプターリガンドによる不妊症の治療
JP2025501239A5 (https=)
WO2024206740A1 (en) Methods and uses for treating nausea and emesis
CN116549428B (zh) 4-羟基异亮氨酸的新用途
US20240043545A1 (en) Methods and compositions for treatment of thyroid eye disease
US12599620B2 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
CN118488853A (zh) 组合疗法
HK40128497A (zh) 使用gip/glp1共激动剂用於治疗的方法
HK40127982A (zh) 使用gip/glp1共激动剂用於治疗的方法
Zeng et al. Balancing efficacy and safety: glucokinase activators in glycemic and metabolic management of type 2 diabetes mellitus—a meta-analysis
JPWO2005018649A1 (ja) 最終糖化産物生成抑制剤
CN121969358A (zh) 选择性雄激素受体调节剂(sarm)化合物在长期体重管理中的用途
Mahmoud et al. Endocrine and Sexual Problems in Adult and Pediatric Hemodialysis and Peritoneal Dialysis Patients
RU2022112615A (ru) Способы лечения тяжелой инсулинорезистентности путем прерывания предачи сигнала глюкагонового рецептора
NZ741097A (en) Antigen-binding proteins that activate the leptin receptor